IBO

Impact BioMedical Inc. (IBO) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 5.8 (Moderate)

ROIC of 14.9% indicates acceptable capital efficiency, but without peer context it reads as solid rather than structurally superior versus comparable operators.

Near-zero net debt to EBITDA reduces balance-sheet drag and supports flexibility, yet peers with stronger liquidity still hold a clearer resilience advantage.

Low leverage can preserve optionality through cyclical stress, but it does not by itself create a durable demand or margin edge versus peers.

Weaknesses

Score:

Current ratio of 0.16 signals acute short-term liquidity pressure, leaving IBO materially weaker than peers with more balanced working-capital coverage.

Quick ratio of 0.13 implies limited near-cash resources, which constrains operating flexibility and typically trails stronger peer liquidity profiles.

Cash conversion cycle of 1,706 days indicates severe working-capital inefficiency, far worse than peers and a direct drag on structural financial quality.

Opportunities

Score:

If working-capital intensity normalizes, liquidity and funding efficiency could improve materially, narrowing the gap with peers that already convert cash faster.

Capital-light deleveraging is already visible, so incremental balance-sheet improvement could strengthen relative positioning if peers remain more levered.

ROIC above the cost of capital suggests room to compound value if operational execution improves, though peers with stronger cash conversion remain better positioned.

Threats

Score:

Persistent working-capital strain can force reliance on external funding, making IBO more vulnerable than peers during tighter credit conditions.

Liquidity weakness raises execution risk because even modest demand or collection shocks can pressure operations more than at better-capitalized peers.

Extremely long cash conversion cycles can erode competitive flexibility over time, especially versus peers that recycle capital faster and fund growth internally.

Overall Score

Score:

IBO’s modest capital efficiency is outweighed by severe liquidity and working-capital weakness, leaving its structural positioning below most peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Impact BioMedical Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →

Invetso is not affiliated with or regulated by the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), or any other financial regulatory authority. The analyses, scores and all the information provided by Invetso are strictly for informational purposes only and do not constitute financial advice, recommendations, or an offer to buy or sell any securities. Invetso is not a registered financial advisor, broker-dealer, or investment advisor, and it does not provide personalized investment, legal, or tax advice. The content provided on this website is not intended to serve as a substitute for professional advice. Users should conduct their own research and consult with a qualified financial advisor before making any investment decisions. All analysis, data, and information presented on this site are based on publicly available information and should be used at the user’s own risk. Invetso does not guarantee the accuracy, completeness, or timeliness of any information or data provided, nor does it endorse any specific securities, companies, or strategies. Any reliance you place on such information is strictly at your own risk. While we strive to provide accurate and up-to-date information, Invetso makes no warranties or representations regarding the completeness, accuracy, or reliability of any analyses or data on our platform, and any such information is subject to the terms and conditions of the Invetso Terms of Service. Our analyses are generated using AI technologies and AI-generated content may contain errors or inaccuracies. Use the information at your own risk. Our platform may contain links to third-party websites, for which we are not responsible for the content or accuracy of information. Invetso shall not be liable for any loss or damage arising from the use of our services. By using this website, you agree that Invetso is not responsible for any losses, damages, or financial outcomes that may result from your use of the information, tools, or resources provided. We recommend consulting with a licensed financial professional before making any investment decisions.

For more details, please refer to our Terms of Service and Privacy Policy.